Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer

Howard I. Scher, David Kelsen, Leonard Kalman, Larry Jones, Joseph Burchenal, Richard J. Gralla

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.

Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume12
Issue number2
DOIs
StatePublished - Feb 1984
Externally publishedYes

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Cells
Vindesine
Cisplatin
Toxicity
Testing
Hypersensitivity
carboxyphthalato-1,2-diaminocyclohexaneplatinum
1,2-cyclohexanediamine
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer. / Scher, Howard I.; Kelsen, David; Kalman, Leonard; Jones, Larry; Burchenal, Joseph; Gralla, Richard J.

In: Cancer Chemotherapy and Pharmacology, Vol. 12, No. 2, 02.1984, p. 101-103.

Research output: Contribution to journalArticle

Scher, Howard I. ; Kelsen, David ; Kalman, Leonard ; Jones, Larry ; Burchenal, Joseph ; Gralla, Richard J. / Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer. In: Cancer Chemotherapy and Pharmacology. 1984 ; Vol. 12, No. 2. pp. 101-103.
@article{0850329c723b4592b90a6d3dd93a27bc,
title = "Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer",
abstract = "A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.",
author = "Scher, {Howard I.} and David Kelsen and Leonard Kalman and Larry Jones and Joseph Burchenal and Gralla, {Richard J.}",
year = "1984",
month = "2",
doi = "10.1007/BF00254599",
language = "English (US)",
volume = "12",
pages = "101--103",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer

AU - Scher, Howard I.

AU - Kelsen, David

AU - Kalman, Leonard

AU - Jones, Larry

AU - Burchenal, Joseph

AU - Gralla, Richard J.

PY - 1984/2

Y1 - 1984/2

N2 - A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.

AB - A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.

UR - http://www.scopus.com/inward/record.url?scp=0021339997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021339997&partnerID=8YFLogxK

U2 - 10.1007/BF00254599

DO - 10.1007/BF00254599

M3 - Article

C2 - 6697424

AN - SCOPUS:0021339997

VL - 12

SP - 101

EP - 103

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -